Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver （CQMU）

NCT05007665 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Chongqing Medical University as lead sponsor.

NCT NCT05007665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05007665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver （CQMU）
Lead sponsor
The Second Affiliated Hospital of Chongqing Medical University
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2021
Completion date
December 30, 2023
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse reaction to vaccine, covid19, liver diseases